As cytokines and 1,25-dihydroxyvitamin D [1, 2 D] appear to have an important role in bone homeostasis, we examined the possibility that human immunodeficiency virus (HIV)-infected patients, characterized by enhanced levels of proinflammatory cytokines and 1,25-(OH) 2 D deficiency, have disturbed bone metabolism by analyzing serum markers of bone formation (osteocalcin) and bone resorption (C-telopeptide) in 73 HIV-infected patients. HIV-infected patients with advanced clinical and immunological disease and high viral load were characterized by increased C-telopeptide and particularly by markedly depressed osteocalcin levels. HIV-infected patients had enhanced activation of the TNF system. Serum concentrations of p55 and p75-TNF receptors were negatively correlated with osteocalcin, and p75-TNF receptor was positively correlated with C-telopeptide. HIV-infected patients with advanced disease also had decreased serum concentrations of 1,25-(OH) 2 D, but this parameter was not correlated with osteocalcin or C-telopeptide. During 24 months with highly active antiretroviral therapy there was a marked rise in serum osteolcalcin levels together with a profound fall in viral load and TNF components and a marked rise in CD4 ϩ T cell counts. Also, there was a shift from no correlation to a significant correlation between osteocalcin and C-telopeptide levels during such therapy. The present study suggests disturbed bone formation and resorption during HIV infection. Our findings indicating synchronization of bone remodeling during highly active antiretroviral therapy may represent a previously unrecognized beneficial effect of such therapy and expand our knowledge of the interactions between cytokines and bone in the bone-remodeling process. (J Clin Endocrinol Metab 84: [145][146][147][148][149][150] 1999) 
I
NTERACTIONS between cells of the skeletal and immune system are important for the maintenance of bone homeostasis (1) . These cellular circuits are in part mediated by specific cytokines, and changes in levels of these mediators may result in altered bone remodeling and disease (1) (2) (3) . For example, cytokines such as interleukin-1 (IL-1), IL-6, IL-11, and tumor necrosis factor-␣ (TNF␣) may stimulate osteoclast activity (1) (2) (3) , and enhanced IL-6 levels appear to play a pathogenic role in the enhanced bone resorption of postmenopausal osteoporosis (4, 5) . Some of these cytokines (e.g. IL-1 and TNF␣) may also inhibit bone formation exerted by their negative regulatory effects on osteoblasts (1, 6, 7) . This inhibitory effect on osteoblasts combined with stimulation of osteoclasts suggest a pathogenic role for these cytokines in bone disorders characterized by increased resorption combined with decreased formation of bone, e.g. osteomyelitis, rheumatoid arthritis, and certain malignancies (1) .
Persistent activation of proinflammatory cytokines such as IL-1, and in particular TNF␣, appears to play an important pathogenic role in human immunodeficiency virus (HIV) infection (8 -10) . This proinflammatory activation may enhance HIV replication, contribute to the development of immunodeficiency and certain clinical manifestations (10, 11) , and be related to the endocrine abnormalities seen in HIVinfected individuals (12, 13) . Thus, we have previously demonstrated a marked decrease in serum levels of 1,25-dihydroxyvitamin D 3 [1, 2 D] in HIV-infected patients correlated with the degree of immunodeficiency, possibly related to enhanced TNF␣ activity (14 -16) . Vitamin D metabolites have complex effects on the bone system, with stimulatory effects on both formation and resorption (1, 17) . Of particular interest, the stimulatory effects of 1,25-(OH) 2 D on osteoblast function appear to be inhibited by TNF␣ (18, 19) . Based on the roles of cytokines and 1,25-(OH) 2 D in bone homeostasis, we examined the possibility that HIV-infected patients, characterized by enhanced levels of proinflammatory cytokines and 1,25-(OH) 2 D deficiency, may develop disturbed bone metabolism, as evaluated by serum markers of bone formation and resorption.
Subjects and Methods

Patients and controls
Seventy-three HIV-infected patients (58 men and 15 women; median age, 38 yr; range, 19 -58 yr) were included in the study (Table 1) . Clin-ically, 16 patients were classified as asymptomatic HIV-infected patients [Centers for Disease Control and Prevention (CDC) group A], 19 patients were classified as symptomatic non-AIDS patients (CDC group B), and 38 were classified as acquired immunodeficiency syndrome (AIDS) patients (CDC group C) (20) . Patients with any of the following criteria were excluded from the study: recent history of extended bed rest, previous diagnosis of metabolic bone disorders or endocrine diseases, serum creatinine more than 100 mol/L or alanine aminotransferase more than 50 U/L, abuse of drugs or alcohol, and the use of corticosteroids, diuretics, cytostatics, anticoagulants, nonsteroid antiinflammatory drugs, forscarnet, or any other drugs with known effect on bone metabolism. At the time of the study, none of the patients had any signs or symptoms of acute or exacerbation of chronic disease. In the crosssectional testing (see below), 49 patients received antiretroviral therapy (35 zidovudine, 3 didanosine, and 11 zidovudine in combination with lamivudine). Forty-nine patients received Pneumocystis carinii prophylaxis (8 aerosolized pentamidine, 30 dapsone, and 11 trimetoprim-sulfametoxazole). Sixteen of the patients were followed during highly active antiretroviral therapy (HAART), and all of these received indinavir (800 mg, 3 times daily) in combination with zidovudine (250 mg, twice daily) and lamivudine (150 mg, twice daily). Controls in the study were 25 sex-and age-matched HIV-seronegative healthy blood donors (19 men and 6 women; median age, 39 yr; range, 20 -65 yr). Informed consent for blood sampling was obtained from all patients and controls. Blood samples for the study were drawn between 0800 -1000 h after an overnight fast as previously described (9) . The serum samples were stored at Ϫ70 C until analysis and were thawed only once. All samples from a given patient were analyzed at the same time to minimize the run to run variability.
Analyses of osteocalcin and C-telopeptide in serum
Osteocalcin levels were measured by an immunoradiometric assay (Instar Corp., Stillwater, MI) detecting intact osteocalcin-(1-49). Degradation products of the C-terminal telopeptides of type I collagen (Crosslaps) were measured by an enzyme immunoassay (EIA; Osteometer Bio Tech, Herlev, Denmark). 2 (14) . Intact PTH was quantified using a solid phase, two-site chemiluminescent enzyme immunometric assay (Diagnostic Products Corp., Los Angeles, CA) (16).
Quantification of 1,25-(OH)
EIA for detection of TNF␣ and soluble TNF receptors (TNFRs)
The soluble TNFRs, p55-and p75-TNFR, were analyzed by EIAs as previously described (21) . TNF␣ was quantified by EIA (Medgenix, Fleurus, Belgium) (9).
Miscellaneous
Serum levels of ionized calcium and magnesium were analyzed as described previously (16) . Plasma (ethylenediamine tetraacetate) HIV ribonucleic acid levels were measured by quantitative reverse PCR (Amplicor HIV Monitor, Roche Diagnostic Systems, Branchburg, NJ; detection limit, 200 copies/mL). CD4 ϩ and CD8 ϩ T cell counts in peripheral blood were determined by immunomagnetic quantification (9) .
Statistical analyses
When comparing more than two groups, the Kruskal-Wallis test was used. If a significant difference was found, the Mann-Whitney U test (two-tailed) was used to determine the differences between each pair of groups. Coefficients of correlation were calculated by the Spearman rank test. During HAART, each parameter were compared with baseline by Wilcoxon's rank sum test for paired data. Data are given as medians and 25-75th percentiles if not otherwise quoted. P values are two-sided and considered significant when Ͻ0.05.
Results
Serum levels of osteocalcin and C-telopeptide in HIVinfected patients
We first measured serum levels of osteocalcin and Ctelopeptide as indirect parameters of bone formation and resorption, respectively. Patients in CDC group C had significantly decreased osteocalcin levels compared both with healthy controls and other HIV-infected patients (Fig. 1 ). In fact, 11 of the patients, all in CDC group C, had osteocalcin levels below the detection limit of the assay (0.034 nmol/L) compared with 1 healthy control (Fig. 1) . In contrast to the decreased osteocalcin levels, patients in CDC group C, but not those in CDC groups A and B, had raised C-telopeptide levels with more than a 2-fold increase compared with controls in 10 of the patients, representing those AIDS patients with the most advanced disease. The abnormalities in serum concentrations of osteocalcin and C-telopeptide were also found when males and females were examined separately (data not shown). Among HIV-infected patients, there was no correlation between osteocalcin and C-telopeptide levels (r ϭ Ϫ0.06; P ϭ 0.62). Although C-telopeptide was negatively correlated with CD4 ϩ T cell counts (r ϭ Ϫ0.28; P Ͻ 0.02), osteocalcin levels were positively correlated (r ϭ 0.46; P Ͻ 0.001) with numbers of this lymphocyte subset in the patient group. Osteocalcin levels were also positively correlated with CD8
ϩ T cell counts (r ϭ 0.28; P Ͻ 0.03) and negatively correlated with plasma viral load (r ϭ Ϫ0.33; P Ͻ 0.03).
Serum levels of osteocalcin and C-telopeptide in relation to activation of the TNF system
HIV-infected patients had markedly elevated serum levels of TNF␣ and both types of soluble TNFRs, with particularly high levels in CDC group C (Table 1) . Interestingly, there was a strong inverse correlation between levels of both p55-TNFR and p75-TNFR and osteocalcin (Fig. 2) . Also, TNF␣ tended to be inversely correlated with osteocalcin levels (r ϭ Ϫ0.24; P ϭ 0.06). In contrast to the negative correlation with osteocalcin, p75-TNFR were positively correlated with C-telopeptide (Fig. 2) . Notably, also within the AIDS group, but not within CDC groups A and B, C-telopeptide was significantly correlated with soluble p75-TNFR (r ϭ 0.50; P ϭ 0.002), reflecting that the increase in C-telopeptide concentrations was mostly restricted to AIDS patients with the most marked activation of the TNF system.
Osteocalcin and C-telopeptide in relation to 1,25-(OH) 2 D and PTH levels
As previously reported by us (14 -16), AIDS patients had a profound decrease in serum levels of 1,25-(OH) 2 D associated with decreased PTH and normal or decreased calcium and magnesium levels (Table 1) . However, there was no significant correlation between 1,25-(OH) 2 D, calcium, magnesium, or PTH levels and neither osteocalcin nor C-telopeptide levels (data not shown).
Parameters of bone remodeling during HAART
To further elucidate the interaction among HIV, TNF, and bone remodeling, we studied the effect of HAART on serum FIG. 1. Serum levels of osteocalcin (A) and degradation products of the C-terminal telopeptides of type I collagen, C-telopeptide (B), in 3 clinical groups of HIV-infected patients and in 25 healthy controls. CDC A, asymptomatic HIV-infected patients (n ϭ 16); CDC B, symptomatic non-AIDS patients (n ϭ 19); CDC C, AIDS patients (n ϭ 38). The data in box plots are given as medians, 25-75th percentiles, and ranges. **, P Ͻ 0.01; ***, P Ͻ 0.001 (vs. controls). @@, P Ͻ 0.01; @@@, P Ͻ 0.001 (vs. CDC group B). #, P Ͻ 0.05; ###, P Ͻ 0.001 (vs. CDC group A).
FIG. 2.
Correlations between serum levels of osteocalcin (A) and degradation products of the C-terminal telopeptides of type I collagen, C-telopeptide (B), and serum levels of soluble p55-and p75-TNFR in 73 HIV-infected patients. **, P Ͻ 0.01; ***, P Ͻ 0.001. levels of osteocalcin and C-telopeptide in 16 HIV-infected patients who were followed for 24 months. At baseline, Ctelopeptide levels were different from the corresponding levels in the AIDS group presented in the cross-sectional study (Fig. 1) . However, only 5 of the 16 patients receiving HAART were classified in the AIDS group, and most of these had less advanced disease than the AIDS patients with elevated C-telopeptide levels described in Fig. 1 . After initiating therapy, there was a marked decrease in viral load [maximal decrease in HIV ribonucleic acid copies/mL: 2.29 (range, 1.43-2.67) log 10 ; P Ͻ 0.01] and levels of TNF components (P Ͻ 0.01), and a marked increase in CD4 ϩ T cell counts [maximal increase, 110 (range, 60 -155) ϫ 10 6 /L; P Ͻ 0.01]. Concomitantly, there was a significant and prolonged increase in osteocalcin levels (Fig. 3) . In fact, HAART induced a rise in osteocalcin levels from concentrations below the normal range at baseline to levels above those in healthy controls at the end of the study (Fig. 3) . Also, serum levels of C-telopeptide ( Fig. 3 ) and PTH (data not shown) tended to increase in the second part of the study period, but this increase did not reach statistical significance (Fig. 3) . Notably, although there was no correlation between serum levels of osteocalcin and C-telopeptide at baseline, after HAART these parameters were significantly correlated when comparing the last serum samples from each patient (Fig. 4) .
Discussion
Decreased osteocalcin levels in serum have previously been reported during HIV infection (22, 23) . However, the present study is, to our knowledge, the first report demonstrating that patients with advanced clinical and immunological HIV-related disease are characterized by both decreased osteocalcin and elevated C-telopeptide levels. Furthermore, these abnormalities indicating disturbed bone remodeling in HIV infection were significantly correlated with increased activity of the TNF system. Finally, concomitant with a fall in viral load and TNF components and an increase in CD4 ϩ T cell counts during HAART, there was a marked increase in osteocalcin levels, suggesting restoration of the bone-remodeling process during such therapy.
Skeletal integrity is maintained by a dynamic process of cellular events, with osteoclastic bone resorption and simultaneous formation of new bone by osteoblasts (1). During normal bone turnover these processes are closely regulated and synchronized. Although osteocalcin levels may not necessarily reflect osteoblast function (1), our findings of markedly decreased osteocalcin and increased C-telopeptide levels during advanced HIV-related disease suggest that there is a disturbance in this synchronized bone-remodeling process in these patients.
We found that the disturbances in bone metabolism during HIV infection were correlated with increased activity of the TNF system. This finding may reflect important pathogenic mechanisms in bone remodeling in HIV infection. Although several cytokines, such as IL-1, IL-6, IL-11, and TNF␣, may stimulate osteoclast activity, some of these cytokines, in particular IL-1 and TNF␣, may also inhibit osteoblast function (1-3). Low PTH levels, as found in HIV-infected patients, may also impair bone formation (24), but we found no cor- relation between PTH and osteocalcin levels. Decreased insulin-like growth factor (25) and increased corticosteroid (26) levels have been found in HIV-infected patients, and these factors may affect bone remodeling (1) . Direct HIV-mediated effects on osteoblasts or precursors of osteoclasts may also play a role (27) (28) (29) . However, although several factors probably are involved, our results suggest that increased activity of TNF␣ and/or cytokines induced by TNF␣ (e.g. IL-1 and IL-6) may play an important role in mediating disturbed bone metabolism during HIV infection. Of particular interest is the recently identified osteoprotegerin and its ligand, which are new members of the TNFR/TNF family and regulate osteoclast differentiation and activation (30) . One possibility could be that HIV-infected patients may also have increased levels of the TNF-related molecule osteoprotegerin ligand, which, in turn, may activate osteoclasts in these patients (30) .
As previously reported by us (14 -16), HIV-infected patients with advanced clinical disease are characterized by markedly decreased serum levels of 1,25-(OH) 2 D combined with decreased PTH and normal or decreased calcium levels, possibly reflecting inhibitory effects of TNF␣ on 1␣-hydroxylase activity and PTH secretion (15, 16) . Although there were no statistical correlations between 1,25-(OH) 2 D and either osteocalcin or C-telopeptide levels, the 1,25-(OH) 2 D deficiency may be of importance for the abnormalities in these markers of bone remodeling in HIV infection. 1,25-(OH) 2 D deficiency may impair the proliferation of osteoblasts and their precursors at different stages of differentiation (1) . Notably, the effect of 1,25-(OH) 2 D on osteoblasts appears to be inhibited by TNF␣ (18, 19) . Thus, it is possible that low 1,25-(OH) 2 D levels may have a synergistic effect with increased TNF activity in the induction of disturbed bone homeostasis during HIV infection.
An interesting finding in the present study was the major alterations in markers of bone remodeling induced by HAART. Thus, the profound effect of such therapy on viral load, CD4 ϩ T cells, and TNF components was associated with a marked rise in serum osteolcalcin levels from concentrations below to levels above those in controls. Furthermore, there was a shift from no to a highly significant correlation between osteocalcin and C-telopeptide, suggesting synchronization of bone remodeling and enhanced bone turnover during HAART. The reasons for these changes in markers of bone remodeling during therapy are uncertain. Although inhibition of direct HIV-mediated effects on osteoblasts and osteoclasts may be involved, it is tempting to hypothesize that these findings at least partly reflect down-regulated activity of TNF and/or other proinflammatory cytokine systems. It has been suggested that therapy inhibiting activation of the transcriptional factor nuclear factor-B, a potent inducer of several proinflammatory cytokines, may hold therapeutic potential in the treatment of osteoporosis and other bone disorders (31) . The present study, suggesting synchronization of bone remodeling along with immunomodulating effects of HAART, may further support such an idea. However, to determine whether the changes in biochemical parameters of bone metabolism during HAART are beneficial, larger long term studies that also include bone density tests will have to be performed.
Decreased bone mineral density has previously been reported in HIV-infected patients (23) , and although the clinical consequences of our findings with disturbed osteocalcin and C-telopeptide levels remain unclear, it is conceivable that if these abnormalities persist over time, they may well lead to clinically significant bone disease. Moreover, our findings suggesting synchronization of bone formation and resorption during HAART may represent a previously unrecognized beneficial effect of such therapy, expanding our knowledge of the interactions between cytokines and bone in the bone-remodeling process.
